6 Results for "

RXFP4

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "RXFP4" in MCE Product Catalog:

Cat. No.: HY-RS12360
Research Areas:  

Others

RXFP4 Human Pre-designed siRNA Set A contains three designed siRNAs for RXFP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS19739
Research Areas:  

Others

Rxfp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rxfp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS26235
Research Areas:  

Others

Rxfp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rxfp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-145278
CAS No.: 2752378-78-0
Purity:  99.82%
Target:  

RXFP Receptor

Research Areas:  

Neurological Disease

RXFP3/4 agonist 2 is a potent, nonpeptide dual RXFP3/4 agonist (EC50=3.1 and 2.7 nM). RXFP3/4 agonist 2 also potently promotes interactions between RXFP3 and β-arrestin-2 with EC50 values in the range of 10-22 nM .
loading...
    loading...
Cat. No.: HY-P11246
CAS No.: 3057097-31-8
Target:  

RXFP Receptor

Research Areas:  

Metabolic Disease

A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a Ki value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (Ki = 602.56 nM) and an inhibitory effect on cAMP (EC50) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC50 of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .
loading...
    loading...
Cat. No.: HY-P992108
CAS No.: 3061442-66-5
Synonyms: RELAX10

Research Areas:  

Cardiovascular Disease

Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .
loading...
    loading...